UPDATE 1-One dose of Novo Nordisk's Wegovy back in supply, FDA website shows [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Food and Drug Administration's website showed on Monday one dose of Novo Nordisk's weight-loss drug Wegovy as available after being in short supply, while three other doses remained in limited availability due to increased demand. The website listed the 1.7 milligram (mg) dose as available — making that and the 2.4 mg dose of the drug available for supply. But lower doses of 1 mg, 0.5 mg and 0.25 mg were still listed as in shortage. The Danish drugmaker did not immediately respond to Reuters' request for a comment. Increasing demand for a type of highly effective diabetes and weight-loss treatment known as GLP-1 agonists has led to supply constraints for drugmakers such as Eli Lilly and Novo Nordisk. Most doses of Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand, according to an update on the health regulator's website earlier this month. (Reporting by Sriparna Roy in Bengalu
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data [Yahoo! Finance]Yahoo! Finance
- Roche says weight loss drug shows promising results in early trial [CNBC]CNBC
- India's Biocon posts Q4 profit fall as higher raw material costs bite [Yahoo! Finance]Yahoo! Finance
- Roche obesity therapy leads to ~19% weight loss in Phase 1 trial [Seeking Alpha]Seeking Alpha
- Denmark Raises Growth Forecast as Novo Nordisk Expands Output [BNN Bloomberg (Canada)]BNN Bloomberg
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/15/24 - Form 6-K
- 5/13/24 - Form 6-K
- 5/13/24 - Form 6-K
- NVO's page on the SEC website